Piramal Pharma Limited has announced that it received an Environment, Social and Governance (ESG) rating of 68.5 from SES ESG Research Pvt. Ltd for the financial year 2024-25. The company disclosed this information to stock exchanges on March 20, 2026, under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

ESG Rating Details

The rating assessment was conducted by SES ESG Research based on publicly available data from the company for FY 2024-25. The pharmaceutical company emphasized that it did not directly engage SES ESG for obtaining this rating.

Voluntary Assessment Process

Piramal Pharma clarified that SES ESG Research voluntarily prepared the ESG report by considering various environmental, social, and governance factors that the company has reported publicly. The rating reflects the company's performance across these sustainability parameters without any direct involvement or commissioning from Piramal Pharma.

Regulatory Compliance and Transparency

The disclosure was made in compliance with SEBI listing regulations, ensuring transparency for stakeholders and investors. The company has also made this information available on its official website at piramalpharma.com, providing easy access to shareholders and other interested parties.

The ESG rating publication by SES ESG Research is available on their official website, offering detailed insights into the methodology and factors considered in the assessment. This voluntary rating provides investors and stakeholders with an independent perspective on the company's sustainability practices and governance standards.

Piramal Pharma Limited has disclosed that the US FDA conducted a routine Good Manufacturing Practices (GMP) inspection at its Digwal facility in Telangana, India. The inspection, which took place from February 9, 2026 to February 13, 2026, resulted in the issuance of a Form-483 with specific observations.

Inspection Details and Outcomes

The regulatory filing revealed key details about the FDA inspection and its conclusions:

Nature of Observations

The company clarified that the 4 observations identified by the US FDA are specifically related to enhancement in procedures and are not connected to data integrity issues. This distinction is significant as data integrity concerns typically carry more serious regulatory implications. The observations have been classified as VAI (voluntary action indicated), which represents a moderate level of regulatory concern requiring corrective action.

Company Response and Compliance Commitment

Piramal Pharma Limited has indicated that it is actively preparing a comprehensive response to address all the observations raised by the US FDA. The company plans to submit this detailed response within the stipulated timelines as required by regulatory protocols.

The pharmaceutical company emphasized its commitment to maintaining the highest standards of compliance and stated that it will work closely with the regulatory agency to comprehensively address all the observations. This collaborative approach demonstrates the company's proactive stance toward regulatory compliance and quality assurance.

Regulatory Context

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to inform stock exchanges about material events that could impact investor decisions. The transparency in reporting such regulatory inspections reflects the company's adherence to disclosure norms and commitment to keeping stakeholders informed about operational developments.